| abstract |
Engineered antibodies against human IL-23p19 and their use in the treatment of inflammatory, autoimmune and proliferative disorders are provided. The present invention is a binding compound such as an antibody or a fragment thereof including a humanized antibody or a chimeric recombinant antibody that binds to human IL-23p19, and is at least one selected from the group consisting of SEQ ID NOs: 32-46 Binding compounds comprising an antibody light chain variable domain or antigen-binding fragment thereof having one, two, or three CDRs are provided. Also included in the present invention is a binding compound that binds to human IL-23p19, comprising an antibody heavy chain variable domain comprising one or more CDR sequences selected from the group consisting of SEQ ID NOs: 15-31 or an antigen-binding fragment thereof. It is. |